Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A Q4 FY2025 earnings call

Management Statement and Operational Highlights

• Fourth Quarter 2025: Revenues were ahead of expectations, BSI book-to-bill was again over 1.0x, and free cash flow was strong at over $200 million.
• 2025 Performance: ELITech and Chemspeed had mid- to high-single-digit organic revenue growth, while NanoString was flat due to U.S. academic funding pressure. Spatial biology orders were up double digits. Innovation engine drove strong product launches at conferences.
• 2026 Outlook: Expect continued market improvements. Fiscal year 2026 guidance includes reported revenue growth of 4%-5%, 1%-2% organic growth, ~1.5% M&A contribution, and constant exchange rate growth of 2.5%-3.5%. Focus on Project Accelerate 3.0 portfolio expansion in post-genomic, diagnostics, and other areas.

Segment Performance

• BioSpin Group: 2025 revenue was $879 million, with a mid-single-digit decline. Solid growth in Chemspeed lab automation was offset by declines in NMR instrumentation. In 2026, expected to be the laggard in revenue growth due to factors like limited ultra-high-field NMR installations.
• CALID Group: 2025 revenue was $1.2 billion, with high-single-digit constant exchange rate growth. Growth in microbiology and infection diagnostics driven by ELITech Molecular Diagnostics, and Optics division growth partially offset by mass spectrometry softness.
• Bruker Nano: 2025 revenue was $1.1 billion, with a low-single-digit decline. Solid growth in spatial biology and biopharma offset by declines in academia and industrial markets. Semiconductor metrology was flat in 2025 but expected to be stronger in 2026.
• BEST Segment: 2025 had a mid-single-digit decline net of intercompany eliminations due to soft superconducting demand for clinical MRI systems. Received major multiyear orders in late 2025 and early 2026 for superconducting wire and research instruments.

Guidance

• Revenue: Fiscal year 2026 reported revenue expected to be $3.57 billion to $3.60 billion, representing 4%-5% growth vs 2025, with 1%-2% organic growth, ~1.5% from M&A, and ~1.5% currency tailwind.
• Operating Margin: Expect organic non-GAAP operating margin expansion of 300-350 bps in 2026, offset by ~50 bps currency headwind, resulting in net expansion of 250-300 bps.
• EPS: Non-GAAP EPS guidance $2.10-$2.15, growth 15%-17% vs 2025, with ~8% currency headwind implying 23%-25% constant exchange rate EPS growth.

Risks

• Geopolitical and Market Risks: Include geopolitical risks, market demand, tariffs, currency exchange rates, competitive dynamics, and supply chains.
• U.S. Academic and Government Uncertainty: Lingering uncertainty in the U.S. academic and government market, despite NIH budget increase and some policy improvements.

Question and Answer

• Q: Puneet Souda on margins and cost initiatives A: Frank mentioned additional cost initiatives expected to yield ~$140 million annualized, with some not effective in Q1/Q2 but effective by Q3. Gerald discussed margin cadence, expecting softer Q1 2026 but stronger Q2-Q4.
• Q: Michael Ryskin on margin execution confidence A: Frank stated cost initiatives are in place and confidence in achieving 250-300 bps operating margin expansion, with Gerald noting steps taken and upcoming effectiveness of cost actions.
• Q: Tycho Peterson on end-market assumptions A: Gerald mentioned biopharma and semi expected low-single-digit growth, clinical microbiology stronger, academic and government soft. Frank added molecular diagnostics expected good growth due to 2025 placements.
• Q: Subhalaxmi Nambi on microbiology and diagnostics product roadmap A: Frank said rapid AST gram-negative positive blood culture expected FDA approval in 2026, with Genius platforms expanding into U.S. market through clinical trials in 2027-2028.
• Q: Douglas Schenkel on Q1 organic revenue A: Gerald explained Q1 2026 organic revenue decline due to tough comps and timing of orders, with semi orders and NMR placements not fully impacting Q1.
• Q: Jake on China end-market mix A: Frank noted China recovering on CRO and biopharma, but Gerald clarified China not assumed to have strong growth in 2026 guide.
• Q: Daniel Brennan on U.S. academic and semis A: Frank said U.S. academic and government bookings down in 2025, expected down in 2026; Gerald clarified semi expected low-single-digit growth in 2026.
• Q: Brandon Couillard on BSI segments and NMR A: Frank said BioSpin expected to be growth laggard in 2026, with NMR installations expected to pick up in 2027-2028; Gerald discussed interest expense and free cash flow conversion expectations.